GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forty Seven Inc (NAS:FTSV) » Definitions » PS Ratio

Forty Seven (Forty Seven) PS Ratio : 242.41 (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Forty Seven PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Forty Seven's share price is $95.51. Forty Seven's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2019 was $0.39. Hence, Forty Seven's PS Ratio for today is 242.41.

The historical rank and industry rank for Forty Seven's PS Ratio or its related term are showing as below:

FTSV's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.14
* Ranked among companies with meaningful PS Ratio only.

Forty Seven's Revenue per Sharefor the three months ended in Dec. 2019 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2019 was $0.39.

Back to Basics: PS Ratio


Forty Seven PS Ratio Historical Data

The historical data trend for Forty Seven's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forty Seven PS Ratio Chart

Forty Seven Annual Data
Trend Dec16 Dec17 Dec18 Dec19
PS Ratio
- - - 99.92

Forty Seven Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 16.29 99.92

Competitive Comparison of Forty Seven's PS Ratio

For the Biotechnology subindustry, Forty Seven's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forty Seven's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forty Seven's PS Ratio distribution charts can be found below:

* The bar in red indicates where Forty Seven's PS Ratio falls into.



Forty Seven PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Forty Seven's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=95.51/0.394
=242.41

Forty Seven's Share Price of today is $95.51.
Forty Seven's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Forty Seven  (NAS:FTSV) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Forty Seven PS Ratio Related Terms

Thank you for viewing the detailed overview of Forty Seven's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Forty Seven (Forty Seven) Business Description

Traded in Other Exchanges
N/A
Address
1490 O’Brien Drive, Suite A, Menlo Park, CA, USA, 94025
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Executives
Dennis Henner director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Kristine M Ball director C/O RELYPSA, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Ann D Rhoads officer: Chief Financial Officer 4000 NORTH FIRST STREET, SAN JOSE CA 95134
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Lightspeed General Partner X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Ultimate General Partner X, Ltd. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Jeremy Liew 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Lightspeed Venture Partners X, L.p. 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Barry Eggers 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Peter Nieh 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Ravi Mhatre 10 percent owner 2200 SAND HILL ROAD, MENLO PARK CA 94025
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Clarus Iii L.l.c. 10 percent owner C/O THE BLACKSTONE GROUP L.P., 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154

Forty Seven (Forty Seven) Headlines

From GuruFocus

Forty Seven to Present at Upcoming Investor Conferences in March

By Marketwired Marketwired 02-25-2020